Lanreotide Autogel 120 mg protocol aims to evaluate GH secretion control in acromegaly patients

Acromegaly is a chronic endocrine disorder characterized by excessive Growth Hormone (GH) and Insulin-like Growth Factor 1 (IGF-1) secretion, typically from a pituitary adenoma. This leads to significant morbidity and mortality if uncontrolled. Current treatments include surgery, radiation, and somatostatin analogs like lanreotide, which suppress GH release by binding to somatostatin receptors. However, achieving optimal GH control remains a challenge for many patients, necessitating ongoing evaluation of treatment efficacy and tolerability.

This protocol outlines a study to evaluate the efficacy and tolerability of Lanreotide Autogel 120 mg in patients with active acromegaly. The primary objective is to assess its effectiveness in controlling Growth Hormone (GH) secretion. The abstract does not specify the study's design (e.g., randomized, open-label), the number of participants (n), the frequency or route of administration beyond Autogel 120 mg, the duration of treatment, or the nature of any control arm. It focuses solely on the overarching goal of evaluating the compound's impact on GH levels.